Literature DB >> 32654354

Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.

Giovanni Quarta1, Mauro Gori1, Annamaria Iorio1, Emilia D'Elia1, James C Moon2, Attilio Iacovoni1, Simone Burocchi3, Erik B Schelbert4,5,6, Paolo Brambilla7, Sandro Sironi7, Sergio Caravita8,9, Gianfranco Parati9,10, Antonello Gavazzi11, Alan S Maisel12, Javed Butler13, Carolyn S P Lam14,15,16, Michele Senni1.   

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a chronic cardiac condition whose prevalence continues to rise, with high social and economic burden, but with no specific approved treatment. Patients diagnosed with HFpEF have a high prevalence of comorbidities and exhibit a high misdiagnosis rate. True HFpEF is likely to have multiple pathophysiological causes - with these causes being clinically ill-defined due to limitations of current measurement techniques. Myocyte, interstitium, microvascular, and metabolic abnormalities have been regarded as key components of the pathophysiology and potential therapeutic targets. Cardiac magnetic resonance (CMR) has the capability to look deeper with a number of tissue characterization techniques which are closer to the underlying specific abnormalities and which could be linked to personalized medicine for HFpEF. This review aims to discuss the potential role of CMR to better define HFpEF phenotypes and to infer measurable therapeutic targets.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Cardiac magnetic resonance; Heart failure with preserved ejection fraction

Mesh:

Year:  2020        PMID: 32654354     DOI: 10.1002/ejhf.1961

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

1.  Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility.

Authors:  Matthew K Burrage; Andrew J Lewis; Jack J J Miller
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-26       Impact factor: 3.947

Review 2.  Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation.

Authors:  Gregorio Zaccone; Daniela Tomasoni; Leonardo Italia; Carlo Mario Lombardi; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2021-04-22

Review 3.  Heart failure with mid-range or mildly reduced ejection fraction.

Authors:  Gianluigi Savarese; Davide Stolfo; Gianfranco Sinagra; Lars H Lund
Journal:  Nat Rev Cardiol       Date:  2021-09-06       Impact factor: 32.419

4.  Analysis of Characteristics of Patients with Non-ST-Segment Elevation Myocardial Infarction by Cardiac Magnetic Resonance Imaging.

Authors:  Shujuan Dong; Yunbo Liu; Wenjing Sun; Chunqiu Wang; Yan Wang; Wenbo Zhao; Shenghui Zhao; Yingjie Chu
Journal:  Med Sci Monit       Date:  2021-10-20

Review 5.  A year in heart failure: an update of recent findings.

Authors:  Lorenzo Stretti; Dauphine Zippo; Andrew J S Coats; Markus S Anker; Stephan von Haehling; Marco Metra; Daniela Tomasoni
Journal:  ESC Heart Fail       Date:  2021-12-16

Review 6.  Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy.

Authors:  Mauro Gori; Emilia D'Elia; Edoardo Sciatti; Michele Senni
Journal:  Card Fail Rev       Date:  2022-07-08

Review 7.  Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets.

Authors:  Paolo Severino; Andrea D'Amato; Silvia Prosperi; Francesca Fanisio; Lucia Ilaria Birtolo; Bettina Costi; Lucrezia Netti; Cristina Chimenti; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2021-07-17       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.